UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Clinical cancer research, 2009-11, Vol.15 (22), p.7085-7091

2009

Volltextzugriff (PDF)

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Clinical cancer research, 2016-12, Vol.22 (23), p.5829-5838

2016

Volltextzugriff (PDF)

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

Clinical cancer research, 2013-04, Vol.19 (8), p.2248-2256

2013

Volltextzugriff (PDF)

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

The New England journal of medicine, 2013-08, Vol.369 (6), p.507-516

2013

Volltextzugriff (PDF)

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

British journal of haematology, 2012-09, Vol.158 (6), p.739-748

2012

Volltextzugriff (PDF)

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

Clinical cancer research, 2012-09, Vol.18 (17), p.4830-4840

2012

Volltextzugriff (PDF)

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

Journal of clinical oncology, 2014-06, Vol.32 (17), p.1797-1803

2014

Volltextzugriff (PDF)

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2012-10, Vol.12 (5), p.310-318

2012

Volltextzugriff (PDF)

Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib

Annals of hematology, 2015-02, Vol.94 (2), p.249-256

2015

Volltextzugriff (PDF)

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Clinical cancer research, 2010-03, Vol.16 (5), p.1673-1681

2010

Volltextzugriff (PDF)

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.TPS449-TPS449

2021

Volltextzugriff (PDF)

Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7057-7057

2013

Volltextzugriff (PDF)

Abstract A6: Association of clinical outcomes and the change in circulating soluble VEGF receptor 2 (VEGFR2) levels in advanced gastric cancer patients treated with telatinib (Tel), capecitabine (X), and cislatin (P)

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A6-A6

2011

Volltextzugriff (PDF)

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8035-8035

2012

Volltextzugriff (PDF)

An association between renal cell carcinoma and lymphoid malignancies: A case series of eight patients

Cancer, 1996-12, Vol.78 (11), p.2421-2426

1996

Volltextzugriff (PDF)

Acquired Circulating Anticoagulants

Hematology/oncology clinics of North America, 1992-12, Vol.6 (6), p.1341-1357

Kunkel, Lori A.

1992

Volltextzugriff (PDF)

Acquired Circulating Anticoagulants in Malignancy

Seminars in thrombosis and hemostasis, 1992-01, Vol.18 (4), p.416-423

Kunkel, Lori A.

1992

Volltextzugriff (PDF)

Autoimmune anemia, neutropenia, Eaton-Lambert syndrome, and cerebellar degeneration in a patient with lymphoid hyperplasia

Southern medical journal (Birmingham, Ala.), 1994-02, Vol.87 (2), p.263-264

1994

Volltextzugriff (PDF)

Metabolic inhibitors render ‘resistant’ target cells sensitive to natural killer cell‐mediated lysis

International journal of cancer, 1981-01, Vol.27 (1), p.73-79

1981

Volltextzugriff (PDF)

CD34+ cell engraftment, ex vivo expansion, and malignant cell depletion following immunomagnetic selection

Journal of hematotherapy, 1998-04, Vol.7 (2), p.175-183

1998

Volltextzugriff (PDF)

Distinctive patterns of microRNA expression in primary muscular disorders

Proceedings of the National Academy of Sciences - PNAS, 2007-10, Vol.104 (43), p.17016-17021

2007

Volltextzugriff (PDF)

IVIG Compared With IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children

Pediatrics (Evanston), 2021-12, Vol.148 (6), p.1

2021

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(89)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Humans
(38)
Life Sciences & Biomedicine
(38)
Female
(23)
Male
(23)
Middle Aged
(23)
Adult
(22)
Aged
(22)
Biological And Medical Sciences
(20)
Oncology
(20)
Medical Sciences
(19)
Hematology
(14)
Pharmacology. Drug Treatments
(11)
Antineoplastic Agents
(10)
Aged, 80 And Over
(9)
Hematologic And Hematopoietic Diseases
(9)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(9)
Dose-Response Relationship, Drug
(8)
Treatment Outcome
(8)
Antineoplastic Agents - Adverse Effects
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)

Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy

Abstract A6: Association of clinical outcomes and the change in circulating soluble VEGF receptor 2 (VEGFR2) levels in advanced gastric cancer patients treated with telatinib (Tel), capecitabine (X), and cislatin (P)

A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1

An association between renal cell carcinoma and lymphoid malignancies: A case series of eight patients

Acquired Circulating Anticoagulants

Acquired Circulating Anticoagulants in Malignancy

Autoimmune anemia, neutropenia, Eaton-Lambert syndrome, and cerebellar degeneration in a patient with lymphoid hyperplasia

Metabolic inhibitors render ‘resistant’ target cells sensitive to natural killer cell‐mediated lysis

CD34+ cell engraftment, ex vivo expansion, and malignant cell depletion following immunomagnetic selection

Distinctive patterns of microRNA expression in primary muscular disorders

IVIG Compared With IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children

Suchergebnisse filtern